Crossing the recent three months, 7 analysts have shared their insights on Avidity Biosciences (NASDAQ:RNA), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
Somewhat Bears can't ignore this one, after seeing this, they might have a change of heart.
| Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings | Last 30D 0 1 0 0 0 1 | 1M Ago 0 3 0 0 0 3 | 2M Ago 2 1 0 0 0 3 | 3M Ago 0 0 0 0 0 0 |
|---|
The 12-month price targets, analyzed by analysts, offer insights with an average target of $68.86, a high estimate of $96.00, and a low estimate of $53.00. Observing a 4.33% increase, the current average has risen from the previous average price target of $66.00.
Exploring Analyst Ratings: An In-Depth Overview In examining recent analyst actions, we gain insights into how financial experts perceive Avidity Biosciences.
| Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target | Eric Schmidt Cantor Fitzgerald Maintains Overweight $96.00 $96.00 | Eric Schmidt Cantor Fitzgerald Maintains Overweight $96.00 $96.00 | Gena Wang Barclays Announces Overweight $63.00 - | Josh Schimmer Evercore ISI Group Lowers Outperform $53.00 $54.00 | Joseph Stringer Needham Maintains Buy $60.00 $60.00 | Josh Schimmer Evercore ISI Group Raises Outperform $54.00 $45.00 | Keay Nakae Chardan Capital Raises Buy $60.00 $45.00 |
|---|
Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations.